Telix Pharmaceuticals Ltd., an Australia-based company, has responded to the recent U.S. Government's Executive Order implementing a "Most-Favored Nation" (MFN) policy for drug pricing. The company has assessed the regulation and anticipates a low likelihood of material impact on its business operations. Telix's unique approach involves a complex supply chain and just-in-time manufacturing for radiopharmaceuticals, making international pricing comparisons challenging. The company generates most of its revenue from the U.S. market, particularly through sales of Illuccix®. Telix emphasizes its commitment to the U.S. market by prioritizing access and pricing strategy and investing in U.S.-based manufacturing and distribution to provide innovative precision medicine products efficiently.